TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed and written informed consent~* Age 18 year or older~* Metastatic or incurable locally advanced lobular breast cancer with confirmation of the lobular histology and E-cadherin loss on a biopsy of a metastatic lesion.~* Metastatic lesion accessible for histological biopsies~* Evidence of progression of disease~* A maximum of two lines of palliative chemotherapy~* WHO performance status of 0 or 1~* Evaluable disease or measurable according to RECIST 1.1~Exclusion Criteria:~* Leptomeningeal disease localization~* History of having received other anticancer therapies within 2 weeks of start of the study drug~* History of immunodeficiency, autoimmune disease, conditions requiring immunosuppression~* Prior treatment with immune checkpoint blockade~* Live vaccine within 2 weeks prior to start of study~* Active other cancer~* Active hepatitis B

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Carboplatin/Atezolizumab (Type: EXPERIMENTAL): Carboplatin AUC=1.5, weekly schedule, maximum 12 administrations Atezolizumab, 1200 mg flat dose, 3-weekly schedule, starting after two administrations of carboplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Gcsf Injection in Women With Repeated Implantaiton Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women between the ages of 18 and 37~* Indication of the Antagonist IVF protocol or indication of a substituted frozen embryo transfer~* Subjects with repetitive embryo implantation failure meaning: a history of 3 embryos transferred including frozen embryo without a positive pregnancy test for women 35 years and younger~* Subjects with repetitive embryo implantation failure meaning: a history of 4 embryos transferred including frozen embryo without a positive pregnancy test for women between the ages of 35 and 37.~* Negative repetitive implantation failure work up~Exclusion Criteria:~* Renal failure or cardiac failure~* Chronic neutropenia~* Past or present cancer history~* Sickle cell anemia~* Lithium treatment~* Voluntary withdrawal from the study~* Use of concomitant medication: DHEA (dehydroepiandrosterone ), CoQ10 (coenzyme Q10), Growth Hormone and Viagra

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 37 Years
- Healthy Volunteers: f

Study Arms:
- Filgrastim (Type: ACTIVE_COMPARATOR): Injection Filgrastim 300 ug intravaginally during an IVF cycle or during an embryo transfer
- Sodium Chloride (Type: PLACEBO_COMPARATOR): Injection of 1 ml of Sodium Chloride intravaginally during an IVF cycle or during an embryo transfer cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The ITALIC Study: Is There A LIfe for Drug-eluting Stents (DES) After Discontinuation of Clopidogrel

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female subject ≥ 18 years of age eligible for PCI with at least one drug eluting stent (name: Xience) implanted in all clinical situations excluding primary PCI for acute MI and treatment of the left main artery.~* Male or female subject ≥ 18 years of age eligible for PCI with at least one DES Xience.~* Patient not pre-treated with protein IIb/IIIa inhibitors (name: abxicimab or eptifibatide) during hospitalization~* Patient pre-treated with aspirin and clopidogrel before PCI~* ASA check at least 24 hours after the interruption of tirofiban~* The subject has given written informed and dated consent to participate in this study.~Exclusion Criteria:~* Subjects not able to give informed consent~* Prior implantation of DES~* Known platelets \< 100 000/µl or known hemorrhagic diathesis~* Oral anticoagulation or treatment with abxicimab or eptifibatide during hospitalization~* ASA check less than 24 hours after the interruption of tirofiban~* Thrombolytic therapy within 4 days before ASA check~* Contra-indication to aspirin or clopidogrel~* Recent major surgery \< 6 weeks~* Evidence of an active gastrointestinal or urogenital bleeding~* Severe liver insufficiency~* Primary PCI for acute MI~* Left main PCI~* Any scheduled surgery during the year after enrollment~* Severe concomitant disease with life expectation \< two years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Developmental Outcomes of Extreme Prematurity, 5-15 Years Postpartum

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Preterm Infant~* Very low birth weight or extremely low birth weight~Exclusion Criteria:~* Missing information regarding birth week and weight

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Normal Development (Type: None): The infant's development level will be assessed using a phone interview with parents
- Abnormal Development (Type: None): The infant's level of development will be assessed using a phone interview with parents

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: High Flow Nasal Cannula in Severe Sepsis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \> 18 yr. with diagnostic criteria for severe sepsis, within 12 hours of admission in the Emergency Room, defined as hypotension after hemodynamic resuscitation, initial lactate \> 4, or persistence of organ dysfunction (oliguria \< 0.5 ml/kg/h, cyanosis, or altered consciousness).(qSOFA 1, 2 or 3)~Exclusion Criteria:~* Patients who require immediate ventilatory support both invasive and non-invasive, defined by severe hypoxemia (PaO2/FiO2 \< 150), severe tachypnea (40 x') with signs of respiratory fatigue or low level of consciousness (Glasgow \< 8).~* Patients with limitation of the therapeutic effort or orders of not CPR.~* Patients not susceptible to treatment with HFNC (facial trauma, tracheostomized, rejection of previous treatments with HFNC).~* Participation in other clinical trials that may affect survival.~* Home treatment with oxygen, CPAP or Non-invasive ventilation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- High-Flow nasal cannula (HFNC) (Type: EXPERIMENTAL): Treatment with HFNC will be adjusted for SpO2 \>92%, even with FiO2 of 0.21, if needed.~The rationale for this HFNC dosage is that minute ventilation can be already reduced with 30 L/min, but functional residual capacity and oxygenation maximally improve at higher flow. On the contrary, flow \>50 L/min is uncomfortable for many patients.~In the case of clinical intolerance, flow will be reduced to 40, 30 or 20 L/min. Yet it is not tolerated, HFNC will be stopped and patients will receive conventional oxygen if required, but will be evaluated as in the HFNC group by intention to treat.
- Conventional therapy (Type: NO_INTERVENTION): Patients assigned to the conventional treatment will receive the standard care given at hospital which consists of adding oxygen on nasal prongs or Venturi mask only if hypoxemia is suggested by SpO2 \< 92% by pulse oximetry.~Target for oxygenation in both arms is SpO2 between 92% and 95%. SpO2 \>95% without oxygen supply is acceptable. On the contrary, SpO2 \<92% may be acceptable when needed for medical reasons, mainly chronic hypercapnic patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Continued Access Protocol for the Evaluation of the OPTIMIZER Smart System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects who are 18 years of age or older~2. Subjects who have a baseline ejection fraction greater than or equal to 25% and less than or equal to 45% by echocardiography.~3. Subjects who, in the opinion of the Investigator (based on the current guidelines for clinical practice), have been treated for heart failure for at least 90 days and are currently receiving appropriate, stable medical therapy during the 30 days prior to enrollment for treatment of heart failure.~4. Subjects who are in New York Heart Association functional Class III and IV at the time of enrollment.~5. Subjects who are willing and able to return for all follow-up visits.~Exclusion Criteria:~1. Subjects who have a potentially correctible cause of heart failure, such as valvular heart disease or congenital heart disease.~2. Subjects receiving any form of inotropic support within 30 days before enrollment, including subjects on continuous IV inotrope therapy.~3. Subjects hospitalized for decompensated heart failure requiring acute treatment with intravenous loop diuretics, IV inotropes or hemofiltration within 30 days before enrollment and baseline testing.~4. Subjects who have a clinically significant amount of ambient ectopy, defined as more than 8,900 PVCs per 24 hours on baseline Holter monitoring.~5. Subjects having a PR interval greater than 375ms.~6. Subjects who are scheduled for a CABG or a PTCA procedure, or who have undergone a CABG procedure within 90 days or a PTCA procedure within 30 days of enrollment.~7. Subjects who have a biventricular pacing system, an accepted indication for such a device, or a QRS width of 130ms or greater.~8. Subjects who have had a myocardial infarction within 90 days of enrollment.~9. Subjects who have mechanical tricuspid valve.~10. Subjects who have a Left Ventricular Assist Device or prior heart transplant.~11. Subjects on dialysis.~12. Subjects who are participating in another experimental protocol.~13. Subjects who are unable to provide informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Optimizer Smart System (Type: EXPERIMENTAL): All eligible subjects will have the Optimizer Smart System implanted and receive cardiac contractility modulation therapy (CCM).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Naldemedine in Participants Undergoing Surgeries That Include a Bowel Resection or Bowel Transection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled to undergo 1 of the following procedures via open (nonlaparoscopic) surgery under general anesthesia:~  * partial small or large bowel resection with primary anastomosis~ * radical cystectomy requiring bowel transection with primary anastomosis~* Planned to be managed postoperatively with an enhanced recovery protocol, which, at a minimum, includes all of the following elements:~  * early removal of the nasogastric tube, which is defined as removal of the nasogastric tube at the end of surgery~ * early ambulation, which is defined as ambulation on Day 1~ * early diet advancement on Day 1~* Planned to receive primary postoperative pain management with opioid analgesia administered by any route.~* American Society of Anesthesiologists (ASA) Physical Status Score of I, II, or III (a normal healthy participant, a participant with mild systemic disease, and a participant with systemic disease, respectively).~Exclusion Criteria:~* Scheduled to undergo a total colectomy or any procedure that results in a colostomy or ileostomy.~* Scheduled for endoscopic or laparoscopic surgery.~* Complete bowel obstruction.~* Complicated inflammatory bowel disease (such as ulcerative colitis or Crohn's disease).~* More than 2 major abdominal surgery (for example, gastrectomy, gastric bypass, gastric sleeve, lap banding, pancreatic resection, hepatectomy, intestinal transplant).~* More than 3 doses of an opioid (regardless of the route of administration) during the 7 days prior to surgery.~* Pregnancy or lactation.~* Presence of peritoneal catheter (for example, for dialysis or chemotherapy).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Naldemedine 1.25 mg (Type: EXPERIMENTAL): Participants will receive 1.25 milligrams (mg) naldemedine twice daily (BID) beginning on the day of surgery (Day 1) and for up to a maximum of 10 days post-surgery.
- Naldemedine 2.5 mg (Type: EXPERIMENTAL): Participants will receive 2.5 mg naldemedine BID beginning on the day of surgery (Day 1) and for up to a maximum of 10 days post-surgery.
- Naldemedine 5 mg (Type: EXPERIMENTAL): Participants will receive 5 mg naldemedine BID beginning on the day of surgery (Day 1) and for up to a maximum of 10 days post-surgery.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive matching placebo BID beginning on the day of surgery (Day 1) and for up to a maximum of 10 days post-surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: BDNF and Motor Learning

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18-45 years~* no past history of psychiatric or neurologic disease.~Exclusion Criteria:~* any neuromuscular disorder that impairs upper extremity motion or seizure history~* Pregnancy~* Indwelling metal or medical device that are incompatible with TMS testing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Balanced Slat Colloid HES 130/0.42 on Coagulation Profiles in Patients Undergoing Spinal Cord Tumor Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients over the age of 20 scheduled for spinal tumor removal and fixation~Exclusion Criteria:~* 1. Renal failure 2. Preexisting congestive heart failure(NYHA III \~ IV) 3. Anemia 4. Coagulopathy 5. Abnormal liver function 6. Anti coagulation/Anti platelet ,edication 7. Foreigner, illiterate 8. Disabled person,

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Valanced salt colloid group (Type: EXPERIMENTAL): None
- Valanced salt crystalloid group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult glaucoma patients who are taking drops: dor-tim and Latanoprost Ophthalmic Solution 0.005% (Lat) and come in for an appointment during the trial period~Exclusion Criteria:~* Patients who had an SLT or glaucoma procedure or surgery within 3 months of enrollment will be excluded. Other exclusion criteria include the logistical inability to follow up with the trial, the inability to relax eye muscles for an accurate tonometry measurement, and the inability to instill medications.~The final determination to be included in the study will be made by the Physician on the day of the appointment.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- full dose lat dor-tim; tim-brim-dor-bim (Type: ACTIVE_COMPARATOR): After baseline IOP measurements, subjects in this arm will use the full dose full dose latanoprost and dorzolamide-timolol in phase 2, and then timolol-brimonidine-dorzolamide-bimatoprost in phase 3.
- tim-brim-dor-bim; full dose lat dor-tim (Type: ACTIVE_COMPARATOR): After baseline IOP measurements, subjects in this arm will use timolol-brimonidine-dorzolamide-bimatoprost in phase 2, and then full dose latanoprost and dorzolamide-timolol in phase 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of MM as per IMWG criteria~* age greater than 17 years~* have received at least 2 but no more than 4 prior lines of therapy~* have failed to respond to the most recently administered anti-MM therapy or have demonstrably progressive disease as defined by accepted standard criteria~* have a life expectancy of at least 3 months~* ECOG performance status \< 3~* at registration haematological values within the following limits:~  1. absolute neutrophil count (ANC) \> 1.0 x 109/L~ 2. platelet count \> 50 x 109/L unsupported~* At registration biochemical values within the following limits~  1. Bilirubin \< 1.5 x upper limit of normal (ULN) and transaminases \< 2 x ULN unless considered secondary to hepatic myelomatous infiltration~ 2. Serum creatinine \< 0.19mMol/L~* Written informed consent~* Must agree to use adequate contraceptive measures if indicated. Specifically, women of childbearing potential (WOCBP) may participate provided they meet the following conditions:~  1. Agree to use at least 2 effective contraceptive methods throughout the study and for 30 days following the study~ 2. Have a negative serum pregnancy test within 24 hours of commencing on study medication~ 3. Male participants with female partners that are WOCBP must agree to use 2 effective contraceptive methods throughout the study and for 30 days following the study~Exclusion Criteria:~* Patients with monoclonal gammopathy of undetermined significance (MGUS) or indolent/smouldering MM~* Known or suspected hypersensitivity to AZA or mannitol~* Patients whose general condition makes them unsuitable for intensive treatment e.g. significant cardiac or pulmonary disease~* Active infections or other illnesses that precludes chemotherapy administration or patient compliance~* Active viral infection with known human immunodeficiency virus (HIV) or viral hepatitis type B or C~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy